title: Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.
abstract: BACKGROUND
  HCV causes acute and chronic hepatitis which can eventually lead to permanent liver damage hepatocellular carcinoma and death. HCV glycoproteins play an important role in HCV entry by binding with CD81 receptors. Hence inhibition of virus at entry step is an important target to identify antiviral drugs against HCV.
  
  
  RESULTS
  The present study elaborated the role of CD81 and HCV glycoprotein E2 in HCV entry using retroviral pseudo-particles of 3a local genotype. Our results demonstrated that HCV specific antibody E2 and host antibody CD81 showed dose- dependent inhibition of HCV entry. HCV E2 antibody showed 50% reduction at a concentration of 1.5 ± 1 μg while CD81 exhibited 50% reduction at a concentration of 0.8 ± 1 μg. In addition, data obtained with HCVpp were also confirmed with the infection of whole virus of HCV genotype 3a in liver cells.
  
  
  CONCLUSIONS
  Our data suggest that HCV specific E2 and host CD81 antibodies reduce HCVpp entry and full length viral particle and combination of host and HCV specific antibodies showed synergistic effect in reducing the viral titer.
authors.affiliation: Division of Molecular Medicine, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan. usmancemb@gmail.com
authors.forename: Usman A
authors.initials: UA
authors.lastname: Ashfaq
authors.forename: Muhammad
authors.initials: M
authors.lastname: Qasim
authors.forename: Muhammad Z
authors.initials: MZ
authors.lastname: Yousaf
authors.forename: Muhammad Tariq
authors.initials: MT
authors.lastname: Awan
authors.forename: Shah
authors.initials: S
authors.lastname: Jahan
mesh_terms: D000998:Antiviral Agents / Q000378:metabolism; D002460:Cell Line; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics* / Q000472:pathogenicity; D006526:Hepatitis C / Q000097:blood / Q000821:virology; D018937:Hepatitis C Antibodies / Q000276:immunology*; D006801:Humans; D008099:Liver / Q000473:pathology / Q000821:virology; D060225:Tetraspanin 28 / Q000378:metabolism*; D014759:Viral Envelope Proteins / Q000276:immunology*; D014771:Virion / Q000235:genetics / Q000472:pathogenicity; D053586:Virus Internalization
chemical_list: D000998:Antiviral Agents; D018937:Hepatitis C Antibodies; D060225:Tetraspanin 28; D014759:Viral Envelope Proteins; C091015:glycoprotein E2, Hepatitis C virus
references.citation: Proc Natl Acad Sci U S A. 2004 May 11;101(19):7270-4
references.pmid: 15123813
references.citation: Virol J. 2009 Jan 27;6:13
references.pmid: 19173711
references.citation: Hepatology. 2005 Nov;42(5):1055-62
references.pmid: 16250048
references.citation: Virol J. 2011 May 20;8:248
references.pmid: 21599979
references.citation: Nat Med. 2008 Jan;14(1):25-7
references.pmid: 18064037
references.citation: Proc Natl Acad Sci U S A. 2004 May 18;101(20):7705-10
references.pmid: 15136748
references.citation: J Microbiol Immunol Infect. 2008 Feb;41(1):4-8
references.pmid: 18327420
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9294-9
references.pmid: 15939869
references.citation: Antimicrob Agents Chemother. 2009 Feb;53(2):401-11
references.pmid: 18936191
references.citation: J Virol. 2006 Jun;80(11):5308-20
references.pmid: 16699011
references.citation: Curr Opin Investig Drugs. 2006 Aug;7(8):727-32
references.pmid: 16955684
references.citation: J Virol. 2005 Sep;79(17):11095-104
references.pmid: 16103160
references.citation: Nature. 2005 Aug 18;436(7053):967-72
references.pmid: 16107837
references.citation: Science. 1999 Jul 2;285(5424):110-3
references.pmid: 10390360
references.citation: Hepatology. 2005 Feb;41(2):265-74
references.pmid: 15660396
references.citation: EMBO J. 2002 Oct 1;21(19):5017-25
references.pmid: 12356718
references.citation: Lab Anim (NY). 2005 Feb;34(2):39-47
references.pmid: 15685191
references.citation: PLoS One. 2008 Jul 16;3(7):e2660
references.pmid: 18628977
references.citation: J Virol. 2004 Feb;78(3):1448-55
references.pmid: 14722300
references.citation: Chem Biol. 2006 Jan;13(1):23-30
references.pmid: 16426968
references.citation: Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7271-6
references.pmid: 12761383
references.citation: World J Gastroenterol. 2006 Aug 14;12(30):4836-42
references.pmid: 16937465
references.citation: J Virol. 2007 Jan;81(1):374-83
references.pmid: 17050612
references.citation: J Biol Chem. 2003 Oct 24;278(43):41624-30
references.pmid: 12913001
references.citation: Am J Pathol. 2007 Feb;170(2):478-89
references.pmid: 17255316
references.citation: Nature. 2005 Aug 18;436(7053):953-60
references.pmid: 16107835
references.citation: FEBS Lett. 2003 Jul 10;546(2-3):385-90
references.pmid: 12832074
references.citation: Leuk Lymphoma. 1994;13 Suppl 1:61-4
references.pmid: 8075582
references.citation: J Exp Med. 2003 Mar 3;197(5):633-42
references.pmid: 12615904
references.citation: Annu Rev Immunol. 1998;16:89-109
references.pmid: 9597125
references.citation: Virology. 2006 Apr 25;348(1):1-12
references.pmid: 16455127
references.citation: J Virol. 2001 Jun;75(12):5550-8
references.pmid: 11356962
references.citation: Curr Opin Investig Drugs. 2004 Aug;5(8):838-50
references.pmid: 15600240
references.citation: Antimicrob Agents Chemother. 2010 Jan;54(1):197-206
references.pmid: 19901090
references.citation: Science. 1998 Oct 30;282(5390):938-41
references.pmid: 9794763
references.citation: Virology. 1998 Sep 15;249(1):32-41
references.pmid: 9740774
references.citation: J Virol. 2009 Dec;83(23):12473-82
references.pmid: 19759151
references.citation: J Virol. 2008 Jan;82(1):569-74
references.pmid: 17942559
references.citation: J Virol. 2005 Jul;79(13):8400-9
references.pmid: 15956584